482 related articles for article (PubMed ID: 11039853)
1. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of neutrophil apoptosis in uremia and relevance of the Fas (APO-1, CD95)/Fas ligand system.
Jaber BL; Perianayagam MC; Balakrishnan VS; King AJ; Pereira BJ
J Leukoc Biol; 2001 Jun; 69(6):1006-12. PubMed ID: 11404388
[TBL] [Abstract][Full Text] [Related]
3. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
Erdoğan B; Uzaslan E; Budak F; Karadağ M; Ediger D; Oral B; Göral G; Ege E; Gözü O
Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648
[TBL] [Abstract][Full Text] [Related]
4. Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF.
Onalan G; Selam B; Baran Y; Cincik M; Onalan R; Gündüz U; Ural AU; Pabuccu R
Hum Reprod; 2005 Sep; 20(9):2391-5. PubMed ID: 15932917
[TBL] [Abstract][Full Text] [Related]
5. Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure.
Nakae H; Narita K; Endo S
J Crit Care; 2001 Jun; 16(2):59-63. PubMed ID: 11481600
[TBL] [Abstract][Full Text] [Related]
6. Soluble Fas and soluble Fas L levels in patients with acute pancreatitis.
Endo S; Inoue Y; Fujino Y; Yamada Y; Sato N; Wakabayashi G; Sakamoto T; Ishikura H; Tanaka T; Inada K; Sato S
Res Commun Mol Pathol Pharmacol; 2000; 108(3-4):179-86. PubMed ID: 11913710
[TBL] [Abstract][Full Text] [Related]
7. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment.
Tinazzi E; Puccetti A; Gerli R; Rigo A; Migliorini P; Simeoni S; Beri R; Dolcino M; Martinelli N; Corrocher R; Lunardi C
Int Immunol; 2009 Mar; 21(3):237-43. PubMed ID: 19181929
[TBL] [Abstract][Full Text] [Related]
8. Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors.
Kondera-Anasz Z; Mielczarek-Palacz A; Sikora J
Apoptosis; 2005 Oct; 10(5):1143-9. PubMed ID: 16151647
[TBL] [Abstract][Full Text] [Related]
9. Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma.
Murakami M; Sasaki T; Miyata H; Yamasaki S; Kuwahara K; Chayama K
Oncol Rep; 2004 Jun; 11(6):1183-6. PubMed ID: 15138553
[TBL] [Abstract][Full Text] [Related]
10. Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus.
Song le H; Binh VQ; Duy DN; Bock TC; Kremsner PG; Luty AJ; Mavoungou E
J Med Virol; 2004 Jun; 73(2):244-9. PubMed ID: 15122799
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of sFas and sFasL during chemotherapy of lung cancer.
Naumnik W; Izycki T; Ossolinska M; Chyczewska E
Exp Oncol; 2007 Jun; 29(2):132-6. PubMed ID: 17704746
[TBL] [Abstract][Full Text] [Related]
12. Significance of Fas and Fas ligand in tuberculous lymphadenitis.
Mustafa T; Mogga SJ; Mfinanga SG; Mørkve O; Sviland L
Immunology; 2005 Feb; 114(2):255-62. PubMed ID: 15667570
[TBL] [Abstract][Full Text] [Related]
13. Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection.
Raghuraman S; Abraham P; Daniel HD; Ramakrishna BS; Sridharan G
J Clin Virol; 2005 Sep; 34(1):63-70. PubMed ID: 16087126
[TBL] [Abstract][Full Text] [Related]
14. Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL.
Jabłońska E; Kiersnowska-Rogowska B; Rogowski F; Parfieńczyk A; Puzewska W; Bukin M
Rocz Akad Med Bialymst; 2005; 50():204-7. PubMed ID: 16358967
[TBL] [Abstract][Full Text] [Related]
15. Serum and follicular fluid levels of soluble Fas and soluble Fas ligand in IVF cycles.
Onalan G; Selam B; Onalan R; Ceyhan T; Cincik M; Pabuccu R
Eur J Obstet Gynecol Reprod Biol; 2006 Mar; 125(1):85-91. PubMed ID: 16140454
[TBL] [Abstract][Full Text] [Related]
16. Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma before and after surgical treatment.
Pignataro L; Arisi E; Sambataro G; Corsi MM
J Surg Oncol; 2003 Jun; 83(2):112-5. PubMed ID: 12772205
[TBL] [Abstract][Full Text] [Related]
17. Seasonal changes of proapoptotic soluble Fas ligand level in allergic rhinitis combined with asthma.
Mezei G; Lévay M; Sepler Z; Héninger E; Kozma GT; Cserháti E
Pediatr Allergy Immunol; 2006 Sep; 17(6):444-9. PubMed ID: 16925690
[TBL] [Abstract][Full Text] [Related]
18. sFas and sFas ligand and pediatric sepsis-induced multiple organ failure syndrome.
Doughty L; Clark RS; Kaplan SS; Sasser H; Carcillo J
Pediatr Res; 2002 Dec; 52(6):922-7. PubMed ID: 12438671
[TBL] [Abstract][Full Text] [Related]
19. Clinical importance of circulating and cellular expression levels of Fas and Fas ligand in pediatric patients with lymphoproliferative malignancies.
Hazar V; Berber Z; Pestereli E; Coskun M; Yesilipek A; Karpuzoglu G; Yegin O
Pediatr Hematol Oncol; 2005; 22(3):247-56. PubMed ID: 16020109
[TBL] [Abstract][Full Text] [Related]
20. [Expression of Fas on monocytes and the level of plasma soluble FasL in patients with chronic renal failure].
Jiang J; Hou F; Liu Z; Liu J; Zhang X
Zhonghua Nei Ke Za Zhi; 2001 Jan; 40(1):25-8. PubMed ID: 11798554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
